Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabete and coronary artery disease
10.3969/j.issn.1671-167X.2015.06.006
- VernacularTitle:尿11-脱氢血栓素B2水平与2型糖尿病合并冠心病患者阿司匹林临床疗效的相关性研究
- Author:
Tengfei LIU
;
Jingwei ZHANG
;
Xiahuan CHEN
;
Xueru FENG
;
Zhongsheng BAI
;
Meilin LIU
- Publication Type:Journal Article
- Keywords:
11-dehydrothromboxane B2;
Aspirin;
Platelet aggregation;
Coronary disease;
Diabetes mellitus;
type 2
- From:
Journal of Peking University(Health Sciences)
2015;47(6):920-924
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To elucidate the correlation between urinary 11-dehydro-thromboxane B2 ( 11 dhTxB2 ) and clinical efficacy of aspirin treatment in patients with type 2 diabete and coronary artery disease ( CAD) . Methods:In this prospective cohort study, 169 aged patients with type 2 diabete accom-panying CAD in Peking University First Hospital were enrolled. The level of urinary 11dhTxB2 was detec-ted using enzyme-linked immuno-sorbent assay. Low aspirin response or high on aspirin platelet reactivity (HAPR) was defined as urinary 11dhTxB2>1 500 ng/g. All the included patients were divided into two groups based on the results, HAPR group and No-HAPR group. Results:Baseline urinary 11dhTxB2 of the patients with type 2 diabete accompanying CAD was ( 3 687 ± 3 052 ) ng/g, while the urinary 11dhTxB2 was (1 954 ± 859) ng/g in patients after 100 mg/d aspirin treatment (P<0. 001). Preva-lence of HAPR in patients with type 2 diabete accompanying CAD were 32 . 5%. Within a mean follow-up time of 12 months, the outcomes occurred more frequently in HAPR group than in No-HAPR group ( P<0 . 05 ) . Conclusion:Urinary 11 dhTxB2 can be recognized as an effective indicator in evaluating aspirin clinical efficacy of patients with type 2 diabete accompanying CAD.
